Correction to: Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial.
出版信息
Circulation. 2019 Feb 19;139(8):e42. doi: 10.1161/CIR.0000000000000657.
Abstract
摘要
相似文献
1
Correction to: Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial.对《股腘动脉紫杉醇洗脱支架的持久临床疗效：Zilver PTX随机试验5年结果》的勘误
Circulation. 2019 Feb 19;139(8):e42. doi: 10.1161/CIR.0000000000000657.
2
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.紫杉醇洗脱支架治疗股腘动脉的持久临床疗效：Zilver PTX随机试验的5年结果
Circulation. 2016 Apr 12;133(15):1472-83; discussion 1483. doi: 10.1161/CIRCULATIONAHA.115.016900. Epub 2016 Mar 11.
3
A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.载紫杉醇聚合物涂层支架与裸金属支架治疗首发股浅动脉病变的比较：BATTLE 试验
JACC Cardiovasc Interv. 2020 Feb 24;13(4):447-457. doi: 10.1016/j.jcin.2019.12.028.
4
A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.聚合物涂层紫杉醇洗脱支架（Eluvia）与无聚合物紫杉醇涂层支架（Zilver PTX）治疗下肢股腘动脉腔内介入治疗（IMPERIAL）：一项随机非劣效试验。
Lancet. 2018 Oct 27;392(10157):1541-1551. doi: 10.1016/S0140-6736(18)32262-1. Epub 2018 Sep 24.
5
ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.ZILVERPASS 研究：在股浅动脉病变中 ZILVER PTX 支架与旁路手术的比较。
J Endovasc Ther. 2020 Apr;27(2):287-295. doi: 10.1177/1526602820902014. Epub 2020 Jan 30.
6
Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.紫杉醇洗脱支架治疗日本股浅动脉疾病的上市后监测研究：12 个月结果。
JACC Cardiovasc Interv. 2016 Feb 8;9(3):271-277. doi: 10.1016/j.jcin.2015.09.035.
7
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.日本紫杉醇洗脱支架治疗股腘动脉疾病的Zilver PTX上市后监测研究：2年结果
Cardiovasc Intervent Radiol. 2019 Mar;42(3):358-364. doi: 10.1007/s00270-018-2110-1. Epub 2018 Nov 8.
8
Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.紫杉醇洗脱支架治疗股腘动脉病变的持续安全性和有效性：来自 Zilver PTX 随机和单臂临床研究的 2 年随访结果。
J Am Coll Cardiol. 2013 Jun 18;61(24):2417-2427. doi: 10.1016/j.jacc.2013.03.034. Epub 2013 Apr 10.
9
Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.紫杉醇洗脱支架治疗股腘动脉支架内再狭窄。
JACC Cardiovasc Interv. 2013 Mar;6(3):274-81. doi: 10.1016/j.jcin.2012.12.118.
10
Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.紫杉醇涂层 Zilver PTX 药物洗脱支架治疗与未涂层器械相比，不会增加长期全因死亡率。
Cardiovasc Intervent Radiol. 2020 Jan;43(1):8-19. doi: 10.1007/s00270-019-02324-4. Epub 2019 Sep 9.
引用本文的文献
1
Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia.糖尿病合并慢性肢体威胁性缺血患者当前管理策略的综合评估
Clin Diabetes. 2021 Oct;39(4):358-388. doi: 10.2337/cd21-0019.
2
Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis.紫杉醇涂层器械治疗≥65 岁老年股腘动脉狭窄患者：ACC PVI 注册分析。
Am Heart J. 2021 Mar;233:59-67. doi: 10.1016/j.ahj.2020.12.004. Epub 2020 Dec 13.
3
Paclitaxel-Coated Balloons and Stents for Lower Extremity Peripheral Arterial Disease Interventions: A Regulatory Perspective for the Practicing Clinician.用于下肢外周动脉疾病干预的紫杉醇涂层球囊和支架：执业临床医生的监管视角
Mayo Clin Proc. 2020 Aug;95(8):1569-1573. doi: 10.1016/j.mayocp.2020.01.035.
4
Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?药物涂层球囊在治疗外周动脉疾病中的安全性问题探讨
Curr Cardiol Rep. 2019 Sep 7;21(10):126. doi: 10.1007/s11886-019-1211-z.
Zotero 插件